- Home
- ADN vs SABS Comparison
ADN vs SABS Comparison
Compare ADN & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADN
- SABS
- Stock Information
- Founded
- ADN 2006
- SABS 2014
- Country
- ADN United States
- SABS United States
- Employees
- ADN N/A
- SABS N/A
- Industry
- ADN Power Generation
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- ADN Utilities
- SABS Health Care
- Exchange
- ADN Nasdaq
- SABS Nasdaq
- Market Cap
- ADN 16.7M
- SABS 19.0M
- IPO Year
- ADN N/A
- SABS N/A
- Fundamental
- Price
- ADN $4.96
- SABS $1.82
- Analyst Decision
- ADN
- SABS Strong Buy
- Analyst Count
- ADN 0
- SABS 5
- Target Price
- ADN N/A
- SABS $12.40
- AVG Volume (30 Days)
- ADN 12.2K
- SABS 246.2K
- Earning Date
- ADN 12-27-2024
- SABS 03-28-2025
- Dividend Yield
- ADN N/A
- SABS N/A
- EPS Growth
- ADN N/A
- SABS N/A
- EPS
- ADN N/A
- SABS N/A
- Revenue
- ADN $8,157,000.00
- SABS $1,512,723.00
- Revenue This Year
- ADN $2,232.99
- SABS N/A
- Revenue Next Year
- ADN $91.56
- SABS N/A
- P/E Ratio
- ADN N/A
- SABS N/A
- Revenue Growth
- ADN 274.35
- SABS N/A
- 52 Week Low
- ADN $1.71
- SABS $1.60
- 52 Week High
- ADN $9.54
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- ADN 44.58
- SABS 36.28
- Support Level
- ADN $4.78
- SABS $2.00
- Resistance Level
- ADN $5.50
- SABS $2.15
- Average True Range (ATR)
- ADN 0.39
- SABS 0.20
- MACD
- ADN 0.01
- SABS 0.03
- Stochastic Oscillator
- ADN 50.91
- SABS 30.99
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.